Voglibose Tablets 0.2 mg, 0.3 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 0.2 mg, 0.3 mg

Reference Brands: Volix®, Vocarb®, Voglimet®, Basen®(EU/Asia)

Category: Diabetes

Voglibose works by inhibiting intestinal alpha-glucosidase enzymes, delaying carbohydrate digestion and glucose absorption. This helps control post-meal blood sugar spikes. It is particularly beneficial for managing postprandial hyperglycemia in type 2 diabetes, improving glycemic control without causing significant hypoglycemia when used as monotherapy.

Product Description: Voglibose is an oral alpha-glucosidase inhibitor used primarily for the management of postprandial blood glucose levels in type 2 diabetes mellitus. It is not FDA-approved in the United States and thus not commercially available there. In the European Union, Voglibose is not broadly authorized but may be marketed in specific regions under national licenses. The drug is extensively approved and utilized in countries like India and Japan, where it is sold under various brand names. It is often used alone or in combination with other antidiabetic agents. Regulatory approvals focus on its efficacy in delaying glucose absorption.